Ivax Pharmaceuticals (UK) Ltd v Astrazeneca AB

Ivax Pharmaceuticals (UK) Ltd v Astrazeneca AB

The presumption in favour of a stay was not rebutted by Ivax; commercial urgency and public interest arguments were undermined by Ivax's conduct and delay. Justice does not require parallel proceedings, so a stay is granted pending EPO determination.

Parties
Claimant: Ivax Pharmaceuticals (UK) Ltd; Defendant: AstraZeneca AB
Jurisdiction
England and Wales
Judgment Date
28 May 2004
Procedural Posture
Patent Revocation / Interlocutory Application for Stay of Proceedings
Outcome
Stay granted pending determination of EPO proceedings.
Legal Topics
Stay of Proceedings, Parallel Litigation, Patent Revocation, Obviousness, Jurisdictional Interaction
Intellectual Property Patent Law Stay of Proceedings Parallel Litigation Patent Revocation Obviousness Jurisdictional Interaction

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 2 Authorities cited 4 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Ivax Pharmaceuticals (UK) Ltd

Claimant

AstraZeneca AB

Defendant

Procedural Posture

Patent Revocation / Interlocutory Application for Stay of Proceedings

Legal Issues

  1. 1 Whether to stay English patent revocation proceedings pending determination of EPO opposition proceedings
  2. 2 Whether justice requires proceedings to continue in parallel with EPO
  3. 3 Appropriate trial date if stay is refused

Ratio Decidendi

The presumption in favour of a stay was not rebutted by Ivax; commercial urgency and public interest arguments were undermined by Ivax's conduct and delay. Justice does not require parallel proceedings, so a stay is granted pending EPO determination.

Court Disposition

Stay granted pending determination of EPO proceedings.

Orders

  • Proceedings stayed pending determination of parallel EPO proceedings.
  • Ivax at liberty to apply to remove the stay if AstraZeneca breaches undertaking to prosecute EPO proceedings with due diligence.